Antiplatelet Therapy and All-Cause Mortality After Transcatheter Aortic Valve Replacement: The TRITAVI Registry.

16 In contrast with these observations, the ARTE trial, which randomized 222 patients (111 to SAPT and 111 to DAPT), showed a strong trend toward a reduced 3-month mortality in the SAPT group (3.6% vs 6.3%, P = 0.37). 7 Further support comes from the CENTER2 (Cerebrovascular Events in Patients Undergoing Transcatheter Aortic Valve Implantation With Balloon-Expandable Valves vs Self-Expandable Valves) study, a pooled patient-level database from 10 clinical studies including a total of 23,562 transfemoral TAVR patients.

also in 5,725 other papers